Life and Health

Shanghai Pharmaceuticals Holding Co., Ltd.

Shanghai Pharmaceuticals Holding Co., Ltd.  (Stock Code: 601607.SH / 02607.HK, included in the SSE 180 Index, CSI 300 Index, and the Morgan Stanley China Index (MSCI)).

Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharma"), a large pharmaceutical conglomerate listed in both Shanghai and Hong Kong, has been included in the Fortune Global 500 for five years running since 2020, as well as being positioned in the Pharm Exec 50. In 2023, it generated a revenue of CNY260.3 billion, making it one of the top two pharmaceutical companies in China and the second-largest distributor of pharmaceutical products in the country.

Shanghai Pharma's Industry

• Shanghai Pharma has 700 products currently in production and boasts 48 varieties with annual sales exceeding CNY100 million each. It is one of the leading companies in China holding the most approvals for rare disease medications, with a total of 21 varieties. The company's commercial distribution network covers 25 provinces and municipalities, serving over 70,000 medical institutions and more than 2,000 retail chain pharmacies.

Shanghai Pharma's R&D

• Shanghai Pharma is among the top list of pharmaceutical companies in China in terms of R&D capabilities. Over the past 10 years, its annual R&D investment has grown at a compound annual growth rate of over 20%. In 2023, the company was included in the list of the best industrial companies for pharmaceutical R&D product lines in China.

Shanghai Healthcare Capital

Shanghai Healthcare Capital (SHC) is a municipal-level investment fund established with approval from the Shanghai Municipal People's Government. Launched by SIIC in December 2020, it aims for a total management size of CNY50 billion. SHC intends to leverage Shanghai's comprehensive advantages in biomedical development and harness industrial resources to create an innovative investment platform focused on the biomedical field that is anchored in Shanghai and Hong Kong, connects with the Yangtze River Delta, and reaches out to the global market.

SHC combines financial capital with industrial resources and operates both domestically and internationally. It focuses on key areas that align with Shanghai's biomedical industry development strategy, including high-end biological products, innovative pharmaceuticals and formulations, advanced medical devices and diagnostics, and innovative business models in the healthcare sector.

Tianjin Pharmaceutical Holdings Co., Ltd.

Tianjin Pharmaceutical Holdings Co., Ltd. ("TJ Pharma") is a major player in China's pharmaceutical industry, characterized by a well-developed industry chain. In 2023, it was ranked among China's top 36 pharmaceutical companies. TJ Pharma has two main board-listed companies, DRT and Tianjin Tianyao Pharmaceuticals Co., Ltd., as well as two firms listed on the National Equities Exchange and Quotations (NEEQ), MEDA Co., Ltd. and NewScen Bio-Pharmaceutical Co., Ltd. In 2023, TJ Pharma reported a revenue of CNY17.976 billion.

TJ Pharma operates over ten major industrial production firms, including DRT, Sixth Traditional Chinese Medicine Factory, Longshunrong, Lerentang, CHING WAN HUNG, Tianjin Tianyao Pharmaceuticals Co., Ltd., Tianyin Heping, and Yumeijing. In addition, it manages several pharmaceutical commercial enterprises, such as Jinyao Pacific, Tianjin Zhongxin Pharmaceutical Co., Ltd., and Jinyao Jinyitang Chain.

To participate in the mixed-ownership reform of TJ Pharma, SIIC led the establishment of Jinhushen Biomedical Technology Co., Ltd. in 2020. On September 29, 2020, the mixed-ownership reform project of TJ Pharma was publicly listed for trading at the Tianjin Property Rights Exchange Centre, and Jinhushen Biomedical Technology Co., Ltd. secured a 67% equity stake in TJ Pharma.

Shanghai Biopharmaceutical Innovation Center

Shanghai Biopharmaceutical Innovation Center a life science open innovation platform founded by Shanghai Pharma in collaboration with leading investors and research institutions.With robust support from the Shanghai Municipal Government and an open-source innovative mindset, SH-INNO is dedicated to fostering synergy by maximizing the benefits of government initiatives, industry knowledge, and healthcare networks. We aim to providing comprehensive support for innovative achievements from concept to product, accelerating the construction of an open-source innovation ecosystem.

SIIC Medical Services

The medical services offered by SIIC include two main projects: SIIC Medical Cosmetology Hospital and SIIC Dongyi Sanatorium (tentative name). SIIC Medical Cosmetology Hospital reflects SIIC's dedication to the Healthy China and Healthy Shanghai plans, in cooperation with Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, a 3A-grade public hospital. This project is an active contribution to the diversified healthcare system in Shanghai and to the establishment of the city as a medical center in Asia. The hospital is located in the landmark building, The Bund SOHO, occupying more than 8,600 square meters. It features departments such as cosmetic surgery, cosmetic dentistry, traditional Chinese medicine aesthetics, dermatology, plastic surgery, medical testing, and imaging. The hospital has introduced a range of high-end professional medical equipment to ensure it provides customized, high-quality services for those seeking aesthetic treatments. It began operations in August 2022.

SIIC Dongyi Sanatorium, developed by SIIC, is in strategic partnership with Huadong Sanatorium. This integrated wellness service project is built on health screenings and encompasses a variety of rehabilitation and health management services. It will feature a medical technology building, a comprehensive health check-up center, special nursing wards, an accommodation facility for health examinations, office buildings, and other ancillary structures, situated in the Dongtan area of Chenjia Town in Chongming. The project spans approximately 78,000 square meters with a total building area of 64,400 square meters and represents an investment of about CNY1.2 billion. Construction started at the end of 2021 and the structure was capped in March 2023. The aim is to finish the overall construction by late September 2024 and to begin trial operations by the end of 2024.